Phase I study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer by Takayama, T et al.
Phase I study of S-1, docetaxel and cisplatin combination
chemotherapy in patients with unresectable metastatic
gastric cancer
T Takayama*,1, Y Sato
1, T Sagawa
1, T Okamoto
1, H Nagashima
1, Y Takahashi
2, H Ohnuma
2, G Kuroiwa
3,
K Miyanishi
1, R Takimoto
1, T Matsunaga
1, J Kato
1, K Yamaguchi
4, K Hirata
4 and Y Niitsu
1
1Fourth Department of Internal Medicine, Sapporo Medical University, School of Medicine, Sapporo, Japan;
2Department of Gastroenterology, Hokkaido
Cancer Center, Sapporo, Japan;
3Department of Internal Medicine, Higashi Sapporo Hospital, Sapporo, Japan;
4First Department of Surgery, Sapporo
Medical University, School of Medicine, Sapporo, Japan
The aim of this dose escalation study was to determine the maximum-tolerated dose (MTD), dose-limiting toxicities (DLTs) and
preliminary efficacy of docetaxel, S-1 and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer.
Seventeen patients received oral S-1 (40mgm
 2 bid) on days 1–14, intravenous cisplatin (60mgm
 2) and docetaxel (60, 70 or
80mgm
 2 depending on DLT) on day 8 every 3 weeks. The MTD of this combination was presumed to be docetaxel 70mgm
 2.A t
this dose level, 40% of the patients (two of five) developed grade 4 neutropenia and 20% (one of five) exhibited grade 3 nausea
during the first course. Therefore, the recommended dose of docetaxel was defined as 60mgm
 2. The DLT was neutropenia. The
response rate (RR) was 88.2% (15 of 17), consisting of one complete response and 14 partial responses. There were two stable
diseases but no progressive disease. Of these 15 responders, four (23.5%) with high VEGF expression showed rapid tumour
regression and achieved downstaging, leading to subsequent curative gastrectomy. Three of these have been disease free for about 3
years, suggesting a complete cure. In conclusion, this regimen was tolerable and showed a quite high RR, with an appreciable
downstaging rate in metastatic gastric cancer.
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Although the incidence of gastric cancer is declining in Western
countries, it is still the fourth most common malignancy world-
wide (Konturek et al, 2006). Except in the countries such as Japan
and Korea, where early detection programs are in place, the disease
is often diagnosed after it becomes metastatic or presents at a
locally advanced stage, and chemotherapy is the only potential
treatment for such advanced gastric cancer.
Over the past several decades, 5-FU-based regimens, either in
combination with other drugs or in monotherapy, have been
accepted as standard chemotherapy for unresectable gastric
cancer, since they have shown a significant survival benefit
compared with the best supportive care (Murad et al, 1993;
Pyrhonen et al, 1995; Glimelius et al, 1997). However, overall
response rates (ORRs) and median survival times (MSTs) of these
regimens, even in combination therapy, have been only 7–51%
and 6–12 months, respectively (Dickson and Cunningham, 2004;
Shah and Schwartz, 2004; Ohtsu et al, 2006).
The recent introduction of a new oral drug, S-1 (Shirasaka et al,
1996), which was developed on the basis of biochemical
modulation to inhibit dihydropyrimidine dehydrogenase and
orotate phosphoribosyltransferase to therapeutic modality for
gastric cancer, has enabled us to increase ORR to 46–74% and
MST to 10.9–14.8 months by its combination with cisplatin
(CDDP), docetaxel or CTP-11, with less toxicity than 5-FU
(Koizumi et al, 2003; Ajani et al, 2006; Inokuchi et al, 2006;
Yamaguchi et al, 2006).
Another relatively new drug, docetaxel, has also proven to be
quite active against gastric cancer, with ORR ranging from 17 to
24% as a single agent (Sulkes et al, 1994; Einzig et al, 1996). In
combination with CDDP, 5-FU or CDDP plus 5-FU or S-1,
docetaxel has shown a higher ORR of 37 to 56% and MST of 9.0 to
14.3 months (Roth et al, 2000; Thuss-Patience et al, 2005; Van
Cutsem et al, 2006; Yamaguchi et al, 2006).
In the present study, we conducted a phase I study of triplet
combination with S-1, docetaxel and CDDP for the treatment of
unresectable metastatic gastric cancer. In this study, we deter-
mined the maximum-tolerated dose (MTD), dose-limiting toxicity
(DLT) and recommended dose (RD), and also examined pre-
liminary therapeutic activity of this combination.
MATERIALS AND METHODS
Patient selection
Patients were entered into the study if they fulfilled the following
eligibility criteria: (1) histologic confirmation of gastric cancer; (2)
unresectable distant metastatic disease (M1 stage according to the
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sJapanese Classification of Gastric Carcinoma; Nishi et al, 1999); (3)
measurable lesion(s) or evaluable disease; (4) agep75 years;
(5)performance status (PS)p2 on the Eastern Cooperative
Oncology Group (ECOG) scale; (6) no prior chemotherapy; (7)
adequate bone marrow function (WBC countX4000ml
 1 and
platelet countX100000ml
 1); (8) adequate liver function (serum
bilirubin levelp1.5mgdl
 1 and serum transaminase levels pthree
times the upper limit of normal); (9) adequate renal function
(serum creatinine levelp1.5mgdl
 1, blood urea nitrogen
levelp25mgdl
 1 and creatinine clearanceX50mlmin
 1.); (10)
no other severe medical conditions; (11) not pregnant or lactating
and (12) provision of written informed consent in accordance with
government guidelines (Good Clinical Practice, by the Ministry of
Health and Welfare of Japan) and guidelines of each institution or
hospital. This study was approved by the ethics committees in each
institution or hospital.
Treatment and dose escalation schedule
S-1 was given orally at a dose of 40mgm
 2 twice daily on days
1–14, followed by a 7-day recovery period. CDDP was adminis-
tered by intravenous infusion for 120min at a dose of 60mgm
 2
on day 8. The starting dose of docetaxel was 60mgm
 2 (level 1),
which was planned to be increased in 10mgm
 2 increments to
80mgm
 2. The starting dose of docetaxel corresponded to 80% of
the recommended dose of the TCF regimen for gastric cancer
reported by Ajani et al (2005a). No intrapatient dose escalation was
allowed. At least three patients were treated at each dose level. This
treatment course was repeated every 3 weeks, with an allowance for
a delay in treatment if toxicity was observed. To avoid CDDP-
induced renal damage, patients were hydrated on days 7–9 with
2000ml 5% dextrose in 0.9% sodium chloride. Prophylactic
administration of antiemetic medication (5-HT3 antagonist plus
corticosteroid) at a standard dose was routinely used to prevent
nausea and vomiting when CDDP was administered. G-CFS was
administered only when grade 4 neutropenia lasting for 3 days, or
grade 3 or 4 neutropenia with fever (DLTs as described bellow) had
been observed. The treatment was repeated unless disease
progression was observed. When patients underwent downstaging
and were deemed able to tolerate a curative surgical operation,
subsequent gastrectomy with lymph node dissection was per-
formed.
Evaluation of the disease
Before a patient could enter the study, the extent of the disease was
determined by physical examination, chest X-ray, gastrointestinal
X-ray, endoscopic examination of the upper gastrointestinal tract,
abdominal ultrasonography, computed tomographic scan of the
abdomen, barium enema and bone scintiscan. Peritoneal meta-
stasis was cytologically confirmed by abdominal ascites puncture
or culdocentesis. Complete blood cell counts, liver function tests,
renal function tests and urinalysis were assessed at least once per
week during treatment. If grade 4 neutropenia was noted, the
neutrophil count was repeated 2 days later to determine whether
the grade 4 neutropenia had lasted for 3 days or longer. Computed
tomographic scanning and imaging of measurable disease were
carried out in every cycle or once in every two cycles. Tumour
response of metastatic lesions was evaluated according to WHO
criteria (World Health Organization, 1979). A complete response
(CR) was defined as the disappearance of all evidence of cancer for
X4 weeks. A partial response (PR) was defined as X50%
reduction in the sum of the products of the perpendicular
diameters of all lesions for 4 weeks, without any evidence of new
lesions or progression on any lesions. No change (disease
stabilization) was defined as less than a 50% reduction or less
than a 25% increase in the sum of the products of the
perpendicular diameters of all lesions, without any evidence of
new lesions. Progressive disease (PD) was defined as a more than
25% increase in X1 lesion or the appearance of new lesions.
Tumour responses of the primary site were evaluated by the
roentgenographic and endoscopic evaluation criteria proposed by
the Japanese Research Society for Gastric Cancer (Nishi et al,
1999). Time to progression (TTP) was defined as the number of
days from the start of treatment to the onset of any progression or
until death. Overall survival (OS) was defined as the number of
days from the start of treatment to death. Downstaging was defined
as the disappearance of all lesions of distant metastases (M0 stage)
for X4 weeks. All responses were reviewed by two external review
panels.
Toxicities were graded according to the National Cancer
Institute Common Toxicity Criteria (NCI-CTC) Version 2.0. The
DLT was defined as one of the following: (1) grade 4 neutropenia
lasting more than 3 days, or grade 3 or 4 neutropenia with fever;
(2) grade 4 thrombocytopenia; (3) grade 3 non-haematological
toxicity and (4) treatment delay of greater than 2 weeks as a result
of toxicity. Dose-limiting toxicity was assessed during the first
course of treatment. The MTD was defined as the dose at which
33% or more patients experienced DLTs during the first course. If
the patients who developed DLT showed response (X50%
reduction in the sum of the products of the perpendicular
diameters of all lesions), the subsequent cycle was started at the
next lower level after complete recovery from the toxic effect of the
previous cycle.
Immunohistochemistry for VEGF
Paraffin-embedded tissue sections of gastric cancer tissue were
deparaffinized in xylene and treated for 20min with 0.6% H2O2 to
block endogenous peroxidase activity. They were incubated
overnight at 41C in a 1:100 dilution of rabbit polyclonal antibody
against VEGF (clone A-20, Santa Cruz Biotechnology, Santa Cruz,
CA, USA). Binding of the primary antibody was detected by
peroxidase staining with an avidin–biotin complex system (Dako,
Carpinteria, CA, USA).
We classified VEGF staining as negative, weak positive or strong
positive according to the percentage of positive cells and staining
intensity by the method of Gong et al (2005), with a minor
modification. In brief, scores for percentage of positive cells were
assigned as follows:p10% of cells positive, 0; 11–25% of cells
positive, 1; 26–50% of cells positive, 2; 51–75% of cells positive, 3
and 475% of cells positive, 4. Scores for staining intensity were
assigned as follows: no staining, 0; light brown, 1; brown, 2 and
dark brown, 3. Overall scores were obtained by multiplying the
percentage score by the intensity score. Overall scores p5 were
defined as negative, overall scores 45 but p15 were defined as
weak positive and overall scores 415 were defined as strong
positive. Two independent pathologists examined five random
fields (300mm
2) of each sample and scored each sample without
knowledge of patient outcome (double blind). An average value of
the two scores was presented in the present study.
RESULTS
Patient characteristics
Between December 2002 and November 2004, 17 patients were
enrolled in this study. No patients had received prior chemo-
therapy or undergone surgical gastrectomy. All patients were
assessable for toxicity and response. Their characteristics are
summarized in Table 1. There were 12 men and five women, with a
median age of 61 years (range 54–75 years). Five patients were PS
0, 11 PS 1 and one PS 2. Histologically, the cancer was of intestinal
type in six patients and diffuse type in 11. Lymph node metastases
were seen in all 17 patients, and 14 of 17 patients had distant
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slymph node metastases consisting of seven with para-aortic lymph
node, five with Virchow lymph node and two with mediastinal
lymph node metastases. Of these 14 patients, eight had additional
distant metastases to liver (2), peritoneum (3) and bone (3). All
three patients with local lymph node metastases had distant
metastases to liver (2), and lung and peritoneum (1). In other
words, distant metastases other than lymph node were found in the
liver of four patients, lung of one patient, bone of three patients
and peritoneal cavity of four patients (one had both lung and
peritoneal metastases).
Toxicities
The first cohort of three patients was entered on level 1, and no
DLTs were observed. The next cohort of three patients received
dose level 2, and one patient experienced grade 3 neutropenia and
grade 2 anorexia, although none of them developed DLT at this
point. Therefore, the next three patients were entered on dosage
level 3. At this level, two of the three patients (66.7%) experienced
grade 4 neutropenia and leukocytopenia, which lasted for more
than 3 days, and grade 3 nausea. Therefore, in order to confirm the
safety of level 2, two additional patients were entered on this level.
However, both exhibited DLT; one exhibited grade 4 neutropenia
lasting for 3 days, as well as grade 3 anorexia. The other developed
grade 4 neutropenia lasting for more than 5 days and required
more than 14 days (20 days) to start the second course. In total,
multiple DLTs of grade 4 neutropenia with grade 3 nausea or
treatment delay occurred in two of the five patients (40%) at level 2.
In order to confirm the safety of level 1, an additional six
patients were enrolled in the level 1 group. Of the nine patients
treated at level 1, no grade 4 neutropenia was observed in the first
course, although grade 3 neutropenia and leukocytopenia were
observed in three of the nine patients (33%), grade 2 anaemia in
one of the nine (11%) and grade 2 nausea in three of the nine
(33%) (Table 2). Based on these results during the first course of
treatment, we concluded that the MTD and RD with this regimen
were level 2 and level 1, respectively, and that the DLT was
neutropenia.
The total number of treatment courses was 80 (51 courses at
level 1, 22 courses at level 2, and 7 courses at level 3). The toxicities
observed during all courses are summarized in Table 3. Neutro-
penia was the most commonly observed haematological toxicity.
No grade 3/4 anaemia or thrombocytopenia occurred in any dose
levels. At levels 2 and 3, grade 4 neutropenia was frequently
observed. At level 1, two of the nine patients (22.2%) developed
grade 4 neutropenia after four or five courses, respectively. In
terms of non-haematological toxicities, grade 3 nausea was
observed in one of the five (20%) at level 2 and two of the three
(66.7%) at level 3. At level 1, no grade 3 nausea or other toxicities
were observed. The nadir of leukocyte and neutrophil counts
occurred around day 17. Neither treatment-related death nor
delayed severe toxicities was observed.
Response
All 17 patients had measurable metastatic lesions. The response
rates (RRs) in levels 1, 2 and 3 were 88.9 (PR 8/9), 80 (CR 1/5, PR 3/
5) and 100% (PR 3/3), respectively (Table 4). The ORR was 88.2%
(1 CR and 14 PR in 17 patients; 95% confidence interval, 63.6–
98.5%). The RRs of the primary tumours, lymph node metastasis
and liver metastasis were 82.4 (14/17), 88.2 (15/17) and 100% (4/4),
respectively. Ascites disappeared in all four patients. The RRs for
the intestinal type and the diffuse type were 100 (6 of 6) and 81.8%
(9 of 11), respectively.
The most striking finding of this study is that four of the 17
patients (23.5%, 1 CR and 3 PR) achieved downstaging and
underwent subsequent gastrectomy. Downstaging was seen at all
Table 1 Patient characteristics
Characteristics Number of patients
Total 17
Male 12
Female 5
Age (years)
Median 61
Range 54–75
Performance status
05
11 1
21
Histology
Intestinal type 6
Diffuse type 11
Metastatic sites
LNs 17
Distant LN
a 14
Liver 4
Peritoneum 4
Bone 3
Lung 1
LN¼lymph node.
aSeven patients with para-aortic lymph node, five patients with
Virchow lymph node and two patients with mediastinal lymph node metastases.
Table 2 Toxicities during the first course
Grade of side effects
Toxicity
Dose
level
Number
of patients 2 3 4
Haematological toxicity
Leukocytopenia 1 9 2 3 0
2 5 212
3 3 121
Neutropenia 1 9 3 3 0
2 5 122
3 3 022
Anaemia 1 9 1 0 0
2 5 000
3 3 100
Thrombocytopenia 1 9 0 0 0
2 5 000
3 3 000
Non-haematological toxicity
Nausea 1 9 3 0 0
2 5 110
3 3 020
Vomiting 1 9 0 0 0
2 5 100
3 3 000
Diarrhoea 1 9 0 0 0
2 5 000
3 3 100
Infection 1 9 0 0 0
2 5 000
3 3 000
GOT/GPT elevation 1 9 0 0 0
2 5 000
3 3 000
Creatinine elevation 1 9 0 0 0
2 5 000
3 3 100
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sdose levels. Of these four cases, three showed histologically
intestinal type and one diffuse type. The CR patient had intestinal
type of adenocarcinoma, which directly invaded into the liver, as
revealed by a CT scan and ultrasonography, and had multiple
distant (para-aortic) lymph node metastasis before treatment.
After four courses of treatment at the level 2 dose, the tumour in
the stomach completely disappeared, as determined by a gastro-
fiberscope examination; lymph node swelling as well disappeared.
After five courses, he underwent total gastrectomy with lymph
node dissection (D2) and partial hepatectomy and was proven to
be histologically CR at all sites. Two of the three downstaged
patients had multiple distant lymph node metastases, and the
remaining patient had multiple liver metastases before treatment.
In these four cases, the median time to response was 42 days,
which was much less than that (65 days) in other PR cases. The
metastatic lesions in all four patients completely disappeared after
2–5 treatment courses. The patients subsequently underwent
surgical gastrectomy with lymph node dissection (D2). Three of
those four patients (1 CR and 2 PR) have been disease free for
about 3 years, suggesting a possible complete cure, and one patient
showed a recurrence of liver metastasis 232 days after surgical
gastrectomy, followed by second-line chemotherapy with CPT-11/
CDDP (Shirao et al, 1997).
As a second-line therapy, seven received CPT-11/CDDP, three
received S-1 monotherapy (Sakata et al, 1998), two paclitaxel
monotherapy (Yamada et al, 2001) and one MTX/5-FU therapy
(Murakami et al, 1987). The three-year survival rates were 23.5%
(4/17) in all cases and 22.2% (2/9) in level 1. The median TTP was
199 days (range 104–1130 days) in all cases and 226 days (range
104–1130 days) in the level 1 group. The median OSs of these
groups were 367 and 389 days, respectively. The median follow-up
time for survival analysis was 1120 days.
Expression of VEGF in gastric cancer tissues
Since docetaxel and S-1 have been suggested to show some
antiangiogenic activity (Hironaka et al, 2002; Hotchkiss et al, 2002)
and a rather rapid disappearance of lesions was observed in four
downstaged patients, we examined the possible correlation
between downstaging (marked therapeutic effect) and VEGF
expression in the tumour tissues by immunohistochemical
staining. In Figure 1, three representative staining patterns of
negative (panels A–C), weak positive (panels D–F) and strong
positive (panels G–I) are shown. The positive immunohisto-
chemical staining for VEGF was observed in 4/4 of the downstaged
cases, whereas it was only in 5/10 of the non-downstaged cases.
When the staining grades (negative, weak positive, strong positive)
were compared between these two groups, the downstaged cases
showed a significantly stronger expression than non-downstaged
cases (P¼0.043 by Mann–Whitney’s U test) (panel J).
DISCUSSION
In this study, we conducted a phase I study of S-1, docetaxel and
CDDP combination for 17 unresectable metastatic gastric cancer
patients and defined RD as S-1 40mgm
 2 (twice daily, days 1–14),
docetaxel 60mgm
 2 (day 8) and CDDP 60mgm
 2 (day 8). Non-
haematologic toxicities including diarrhoea and nausea were
relatively mild and none was greater than grade 3 at the dose of
RD. The DLT was neutropenia. Grade 3/4 neutropenia occurred in
66.7% of patients in all treatment courses. However, it was
generally manageable, and each treatment course could be
performed as planned without a delay in most cases.
For combination chemotherapy regimens, which included S-1,
either a 2-week administration with a 1-week interval protocol
(Hyodo et al, 2003; Yoshida et al, 2006), or 3-week administration
with a 1- to 2-week interval protocol have been reported (Koizumi
et al, 2003; Ajani et al, 2005b). However, a recent post-marketing
surveillance of S-1 disclosed that most toxicities increased during
Table 3 Toxicities during all courses
Grade of side effects
Toxicity
Dose
level
Number
of patients 2 3 4
Haematological toxicity
Leukocytopenia 1 9 4 4 1
2 5 112
3 3 022
Neutropenia 1 9 3 4 2
2 5 023
3 3 022
Anaemia 1 9 2 0 0
2 5 000
3 3 100
Thrombocytopenia 1 9 1 0
2 5 000
3 3 000
Non-haematological toxicity
Nausea 1 9 4 0 0
2 5 110
3 3 121
Vomiting 1 9 1 0 0
2 5 100
3 3 100
Diarrhoea 1 9 2 0 0
2 5 200
3 3 100
Infection 1 9 1 0 0
2 5 110
3 3 100
GOT/GPT elevation 1 9 1 0 0
2 5 100
3 3 000
Creatinine elevation 1 9 1 0 0
2 5 000
3 3 100
Table 4 Objective response
Response TTP (day)
Dose level
Number of
patients CR PR SD PD
Response
rate (%)
Number of
downstaged patients
(%) Median Range
3-year
survival (%)
1 9 0 8 1 0 88.9 2 (22.2) 226 104–1130 2 (22.2)
2 5 1 3 1 0 80.0 1 (20.0) 192 152–1097 1 (20.0)
3 3 0 3 0 0 100.0 1 (33.3) 231 120–833 1 (33.3)
Overall 17 1 14 2 0 88.2 4 (23.5) 199 104–1130 4 (23.5)
CR¼complete response; PD¼progressive disease; PR¼partial response; SD¼stable disease; TTP¼time to progression.
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sthe third week of S-1 administration, often resulting in disconti-
nuation of treatment (Nagashima et al, 2005). In the present study,
therefore, we opted for the 2-week protocol. The reason we
administered docetaxel and CDDP on day 8 and not on day 1, as in
previously reported S-1/CDDP combination studies (Ajani et al,
2005b), was that when we, in the pilot study, administered both
drugs on day 1, we encountered severe neutropenia on days 10–14.
We used an S-1 dosage of 40mgm
 2 twice daily in this study
according to the previous studies (Koizumi et al, 2000; Yoshida
et al, 2006).
Although this is a phase I study recruiting only 17 patients, the
RR was quite high (88%) compared with those of phase II and
phase III studies previously reported. Taking such a high RR into
account, one may assume that the results in terms of TTP (199
days) and MST (367 days) are not impressive. However,
considering that this study included 11 patients with distant
metastases to liver, peritoneum and bone, which are reportedly
poor prognostic factors (Chau et al, 2004; Kim et al, 2007), the
present results of TTP and MST are, we believe, reasonably
acceptable. An important finding in this study was that there were
no cases of PD, unlike in other previous studies. Furthermore, the
most noteworthy result of our study was that four of the 17
patients (23.5%) underwent downstaging, showing a rapid
reduction of the sizes of tumours. As a mechanism of the rapid
tumour regression in these cases, we have postulated that our
regimen has an antiangiogenic effect, since it has been reported
that docetaxel inhibits tumour angiogenesis by interfering with
growth, migration and tubule formation of endothelial cells
(Hotchkiss et al, 2002), and that the combination of S-1 with
CDDP has shown a high RR in VEGF-positive gastric cancer
(Hironaka et al, 2002). This hypothesis was supported by
immunohistochemical examination for VEGF disclosing a sig-
nificantly stronger staining in downstaged patients than in non-
downstaged patients.
Generally, neoadjuvant chemotherapy for stage II/III gastric
cancer is still unacceptable because some cases undergo PD,
thereby leading to an inoperable status during the chemotherapy
before gastrectomy. However, the fact that we observed no PD
patients along with a certain appreciable rate of downstaging in
this study suggests the applicability of our regimen to neoadjuvant
chemotherapy. Therefore, a clinical trial of neoadjuvant chemo-
therapy and a large-scale phase II study of our regimen are
currently underway.
In conclusion, this phase I study revealed the feasibility of the
triple combination of docetaxel, S-1 and CDDP. The DLT was
neutropenia. Our regimen indicated a very high response (88%, 15/
17) in patients with unresectable metastatic gastric cancer. More
importantly, four of the 17 patients (23.5%) achieved downstaging
and underwent subsequent curative gastrectomy. The active
mechanism of our regimen in these four patients is suggested to
involve antiangiogenic activity.
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Non-downstaged cases
Figure 1 VEGF protein expression in gastric cancer tissue. Representative microphotographs of negative (A–C), weak (D–F) and high expression (G–I)
of VEGF. Immunohistochemical staining for VEGF was performed using a specific antibody against VEGF. (A, D, G) H&E staining. (B, E, H) Immunostaining
for VEGF. (C, F, I) Representative areas from (B)( E) and (H), respectively. The downstaged cases showed a significantly higher expression of VEGF than
non-downstaged cases by Mann–Whitney U-test (P¼0.043) (J).
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